AUG 05, 2021 6:00 AM PDT

Nosedive: Poor Nasal Antiviral Responses Linked to Severe COVID

WRITTEN BY: Tara Fernandez

Talking, singing, coughing—all of these can spread COVID-19 from an infected person via respiratory aerosols. These tiny droplets, once inhaled, enter the respiratory system, where the SARS-CoV-2 virus latches onto cell surface receptors and begins to wreak havoc. Many COVID-19 patients present with symptoms that are restricted to the upper respiratory tract. However, those with more severe, life-threatening infections often end up with lasting damage to the lungs.

This phenomenon led researchers to hypothesize that immune events occurring in the nasal passageway may influence the severity of COVID-19 symptoms.

In a study published in the journal Cell, researchers at the University of Mississippi Medical Center took nasal swabs from 58 participants, 35 of whom were COVID-19 patients. The team isolated cells from the swabs and performed single-cell sequencing on them to create individual transcriptomic profiles that were grouped depending on the severity of the patients' experienced.

"Our single-cell sequencing approaches allow us to comprehensively study the body’s response to disease at a specific moment in time," explained team member Alex Shalek from the Ragon Institute. "This gives us the ability to systematically explore features that differentiate one course of disease from another as well as cells that are infected from those that are not.”

Shalek and colleagues found that the patients with severe COVID-19 had very low levels of interferons, a vital part of the antiviral immunological response. Also, these patients were found to have more significant numbers of inflammatory macrophages.

Without a robust antiviral response, the coronavirus may divide and migrate into the lower regions of the airways more easily in severe COVID-19 patients. The activation of inflammatory immune cells could also make things worse by elevating uncontrolled inflammation with serious, often fatal consequences.

Because nearly all the severe COVID-19 samples showed muted antiviral responses, the team suggests that nasal swabs may be used as a predictive tool to identify patients most at risk of a downward spiral.

 


Sources: Cell, Broad Institute.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 20, 2021
Immunology
Coronavirus Variants No Match Against Newly-Discovered Antibody
JUL 20, 2021
Coronavirus Variants No Match Against Newly-Discovered Antibody
Over 940 million people around the world have been fully vaccinated. But, as the World Health Organization warns, t ...
AUG 23, 2021
Microbiology
During a Chronic Viral Infection, Immune Cells May Suffer 'Exhaustion'
AUG 23, 2021
During a Chronic Viral Infection, Immune Cells May Suffer 'Exhaustion'
Several viruses are known to cause chronic infections, one is hepatitis C virus (HCV). Researchers studying these infect ...
AUG 30, 2021
Cancer
A Hot Approach to CAR T Cells
AUG 30, 2021
A Hot Approach to CAR T Cells
Immunotherapy, a type of treatment that targets a patient’s immune system to enhance the natural ability to attack ...
AUG 27, 2021
Health & Medicine
Blood Group and COVID-19 Susceptibility- An Ongoing Debate
AUG 27, 2021
Blood Group and COVID-19 Susceptibility- An Ongoing Debate
Since their discovery, there has been an interest in how ABO blood groups and infectious diseases may be related. In add ...
SEP 01, 2021
Coronavirus
It Seems Not All COVID-19 Patients Develop Antibodies
SEP 01, 2021
It Seems Not All COVID-19 Patients Develop Antibodies
It's been generally assumed that people who get infected with SARS-COV-2 will develop antibodies to the virus, which cau ...
SEP 06, 2021
Microbiology
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
SEP 06, 2021
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
HIV vaccines have remained elusive in part because the virus has a powerful ability to mutate, and there are so many str ...
Loading Comments...